2.4. Procedure, Intervention, and Outcome
sore throat, gastrointestinal symptoms, dyspnea, fever, rhinorrhea, fatigue, cancer, pain, cough, asthma, headache, loss of appetite, loss of smell or taste, chills, diabetes
SORE THROAT, ADVERSE EVENT, CARDIOVASCULAR DISEASE, ADVERSE EVENTS, CANCER, SECONDARY, ASTHMA, HYPERTENSION, DIABETES
Participants were randomized to receive Favipiravir or placebo. Patients in the intervention group received Favipiravir 1600 mg daily for five days (Cytovex, 200 mg, Abidi pharmacological Inc., Tehran, Iran). Patients in the control group received placebo with the same instructions as the intervention group.Demographic data such as age, gender, job, education, height, and weight, date of the first symptom, presenting symptoms (fever, cough, headache, dyspnea, gastrointestinal symptoms, sore throat, rhinorrhea, chills, body pain, loss of appetite, loss of smell or taste, and fatigue), and history of underlying comorbidities (cardiovascular disease, diabetes, hypertension, asthma, and cancer) were documented at the first visit. All patients, even those who did not follow the instructions, were followed up on the 3rd, 7th, 14th, 21st, and 28th day via phone call.The primary outcome of this study was hospitalization. The secondary outcome was adverse events (AEs), which was reported through Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The AEs and patients’ compliance were assessed through the first and second follow-up calls. In the case of incompliance, the reason was asked and recorded.